サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1667705

酵素補充療法の世界市場：2025年

Enzyme Replacement Therapy Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
酵素補充療法の世界市場：2025年
出版日: 2025年02月28日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の酵素補充療法の市場規模は、今後数年間で力強い成長が見込まれます。市場はCAGR9.3％で拡大し、2029年には178億1,000万米ドルに成長すると予測されています。予測期間の成長は、ヘルスケアへの患者アクセスの増加、オーダーメイド治療と個別化医療、規制状況の変化、患者集団の意識の高まりに起因すると考えられます。予測期間における主な動向には、デジタルヘルス統合、患者中心のソリューションへの注力、新たなバイオマーカー研究、精密医療アプローチなどがあります。

希少疾患、慢性疾患、遺伝性疾患の有病率の上昇は、今後数年間の酵素補充療法市場の成長を促進すると予想されます。慢性疾患とは、3カ月以上持続し、時間の経過とともに悪化する可能性のある病気と定義されます。このような疾患は高齢者に多く、一般的に管理は可能ですが治癒は不可能です。例えば、米国を拠点とする非営利団体である米国肺協会は2024年7月、2022年には4,420万人の米国人（人口の13.5％）が医療機関から喘息と診断され、2021年の12.9％から増加したと報告しました。このように、希少疾患、慢性疾患、遺伝性疾患の有病率の上昇は、酵素補充療法市場の成長を促進すると予想されます。

ヘルスケア支出の増加は、今後の酵素補充療法（ERT）市場の成長を促進すると予測されます。ヘルスケア支出とは、一定期間におけるヘルスケア・システムまたは経済圏内のヘルスケア・サービス、物品、活動に割り当てられる総資金のことです。この支出は、研究、開発、臨床試験、検査など、高度に専門化され、高額になりがちなERTの治療を支えるものです。例えば、2022年12月、米国を拠点とする連邦機関Centers for Medicare & Medicaid Servicesは、米国の医療支出が2022年に4.1％増の4兆5,000億米ドルに達し、2021年の3.2％増を上回ったと報告しました。このように、医療費の増加が酵素補充療法市場の成長を後押ししています。

当レポートは、世界の酵素補充療法市場について調査し、市場の概要とともに、酵素タイプ別、投与経路別、用途別エンドユーザー別、地域・国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 酵素補充療法市場の特徴

第3章 酵素補充療法市場の動向と戦略

第4章 酵素補充療法市場- 金利、インフレ、地政学、COVID-19の影響と回復を含むマクロ経済シナリオ

第5章 酵素補充療法の世界成長分析と戦略分析フレームワーク

  • PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の酵素補充療法市場の成長率分析
  • 世界の酵素補充療法の市場規模実績と成長、2019年～2024年
  • 世界の酵素補充療法の市場規模と成長予測、2024年～2029年、2034年予想
  • 世界の酵素補充療法の有効市場規模（TAM）

第6章 酵素補充療法市場セグメンテーション

  • 世界の酵素補充療法市場、酵素タイプ別セグメンテーション、実績および予測、2019～2024年、2024年～2029年、2034年
  • 世界の酵素補充療法市場、投与経路別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 世界の酵素補充療法市場、用途別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 世界の酵素補充療法市場、エンドユーザー別セグメンテーション、実績および予測、2019～2024年、2024年～2029年、2034年
  • 世界の酵素補充療法市場、アガルシダーゼアルファのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 世界の酵素補充療法市場、アガルシダーゼベータのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 世界の酵素補充療法市場、ガルスルファーゼのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 世界の酵素補充療法市場、その他のサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年、2034年

第7章 酵素補充療法市場の地域別および国別分析

  • 世界の酵素補充療法市場、地域別、実績および予測、2019～2024年、2024年～2029年、2034年
  • 世界の酵素補充療法市場、国別、実績および予測、2019～2024年、2024年～2029年予測、2034年予測

第8章 アジア太平洋の酵素補充療法市場

第9章 中国の酵素補充療法市場

第10章 インドの酵素補充療法市場

第11章 日本の酵素補充療法市場

第12章 オーストラリアの酵素補充療法市場

第13章 インドネシアの酵素補充療法市場

第14章 韓国の酵素補充療法市場

第15章 西欧の酵素補充療法市場

第16章 英国の酵素補充療法市場

第17章 ドイツの酵素補充療法市場

第18章 フランスの酵素補充療法市場

第19章 イタリアの酵素補充療法市場

第20章 スペインの酵素補充療法市場

第21章 東欧の酵素補充療法市場

第22章 ロシアの酵素補充療法市場

第23章 北米の酵素補充療法市場

第24章 米国の酵素補充療法市場

第25章 カナダの酵素補充療法市場

第26章 南米の酵素補充療法市場

第27章 ブラジルの酵素補充療法市場

第28章 中東の酵素補充療法市場

第29章 アフリカの酵素補充療法市場

第30章 酵素補充療法市場の競合情勢と企業プロファイル

  • 酵素補充療法市場の競合情勢
  • 酵素補充療法市場の企業プロファイル
    • Biomarin Pharmaceutical Inc.
    • Leadiant Biosciences Inc.
    • Pfizer Inc.
    • Sanofi SA
    • AbbVie Inc.

第31章 その他の大手および革新的企業

  • Johnson & Johnson Services Inc.
  • Alexion Pharmaceuticals Inc.
  • Recordati Rare Diseases Inc.
  • Sangamo Therapeutics Inc.
  • JCR Pharmaceuticals Co. Ltd.
  • Horizon Pharma Public Limited Company
  • Protalix Biotherapeutics Ltd.
  • Amicus Therapeutics Inc.
  • AstraZeneca plc
  • Novartis AG
  • Roche Holding AG
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company

第32章 競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の動向

第35章 潜在性が高い国、セグメント、戦略

第36章 付録

目次
Product Code: r24116

Enzyme replacement therapy (ERT) refers to a sort of medical treatment in which patients with chronic disorders brought on by insufficient or failing enzymes are given alternative enzymes. The body can complete the processes inhibited by the deficit by getting enzyme replacements. It is particularly effective at returning urinary GAG levels to normal and boosting liver and spleen development.

The main types of enzymes used in enzyme replacement therapy include agalsidase alfa, agalsidase beta, galsulfase, other enzyme types that are used in gaucher disease, pompe disease, fabry disease, others. Agalsidase alfa refers to a recombinant human alpha-galactosidase that is used in the treatment of fabry's disease as an enzyme replacement therapy. It has a long half-life and a broad therapeutic spectrum. Patients should be advised about the possibility of infusion-related symptoms and sensitivity. Agalsidase alfa is beneficial to enzyme replacement therapy because it aids in the treatment of Fabry disease. The enzyme replacement therapy is used by hospitals, infusion centers and others that is administered through oral and parenteral route.

The enzyme replacement therapy market research report is one of a series of new reports from The Business Research Company that provides enzyme replacement therapy market statistics, including enzyme replacement therapy industry global market size, regional shares, competitors with enzyme replacement therapy market share, detailed enzyme replacement therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the enzyme replacement therapy industry. This enzyme replacement therapy market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry

The enzyme replacement therapy market size has grown strongly in recent years. It will grow from$11.58 billion in 2024 to $12.48 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to growing early therapeutic discoveries, pioneering treatment approvals, expanded disease understanding, clinical success stories, regulatory support and incentives

The enzyme replacement therapy market size is expected to see strong growth in the next few years. It will grow to $17.81 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing patient access to healthcare, tailored therapies and personalized medicine, regulatory landscape changes, and growing patient population awareness. Major trends in the forecast period include digital health integration, focus on patient-centric solutions, emerging biomarker research, and precision medicine approach.

The increasing prevalence of rare, chronic, and inherited disorders is anticipated to drive the growth of the enzyme replacement therapy market in the coming years. Chronic disease is defined as an illness lasting three months or more that may worsen over time. Such diseases are more prevalent among the elderly and are typically manageable but not curable. For example, in July 2024, the American Lung Association, a U.S.-based non-profit organization, reported that in 2022, 44.2 million Americans (or 13.5% of the population) had been diagnosed with asthma by a healthcare provider, up from 12.9% in 2021. Thus, the rising prevalence of rare, chronic, and inherited disorders is expected to fuel growth in the enzyme replacement therapy market.

The increase in healthcare spending is projected to drive the growth of the enzyme replacement therapy (ERT) market in the future. Healthcare expenditure represents the total funds allocated to healthcare services, goods, and activities within a healthcare system or economy over a given period. This spending supports ERT due to the highly specialized and often costly nature of these treatments, covering research, development, clinical trials, and testing. For example, in December 2022, the U.S.-based federal agency Centers for Medicare & Medicaid Services reported that U.S. healthcare spending grew by 4.1% to reach $4.5 trillion in 2022, outpacing the 3.2% growth in 2021. Thus, rising healthcare expenditures are fueling the growth of the enzyme replacement therapy market.

Product approvals have become a prominent trend gaining traction in the enzyme replacement therapy market. Various enzyme replacement therapy medications introduced by major players are securing approvals in the market. For example, in February 2023, Lamzede (velmanase alfa) received approval from the Food and Drug Administration, a US-based federal agency of the Department of Health. Lamzede is the first enzyme replacement therapy sanctioned in the United States for treating non-central neurological indications of alpha-mannosidosis, a rare genetic disorder characterized by the absence of the alpha-mannosidase enzyme. Administered as a 10mg injection once a week, Lamzede aids patients in regaining normal cellular function by mimicking the action of the alpha-mannosidase enzyme, thereby restoring healthy cellular functioning.

Major companies in the enzyme replacement therapy (ERT) market are strategically focusing on innovative treatment products and obtaining approvals for Pompe disease therapy to address the unmet medical needs of patients with late-onset Pompe disease. In response to the pressing medical needs for late-onset Pompe disease patients in the European Union, Amicus Therapeutics, a US-based biotechnology company, secured approval and launched a new Pompe disease therapy in June 2023. The treatment, comprising Pombiliti (cipaglucosidase alfa) and Opfolda (miglustat), serves as an enzyme replacement therapy for adults with late-onset Pompe disease, supported by clinical data and driven by potential market opportunities and regulatory backing.

In July 2024, Crosswalk Therapeutics Inc., a biotechnology company based in the United States, acquired Codexis Inc. for an undisclosed sum. This acquisition allows Crosswalk Therapeutics to broaden its expertise, integrating Codexis's advanced enzyme engineering technology into its offerings. Codexis Inc. is a U.S.-based company specializing in enzyme engineering.

Major companies operating in the enzyme replacement therapy market include Biomarin Pharmaceutical Inc., Leadiant Biosciences Inc., Pfizer Inc., Sanofi S.A., AbbVie Inc., Johnson & Johnson Services Inc., Alexion Pharmaceuticals Inc., Recordati Rare Diseases Inc., Sangamo Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Horizon Pharma Public Limited Company, Protalix Biotherapeutics Ltd., Amicus Therapeutics Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Retrophin Inc., Abeona Therapeutics Inc., Orchard Therapeutics plc, Ultragenyx Pharmaceutical Inc.

North America was the largest region in the enzyme replacement therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global enzyme replacement therapy market report during the forecast period. The regions covered in the enzyme replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the enzyme replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The enzyme replacement therapy market includes revenues earned by entities by providing Sebelipase alfa, Elosulfase alfa, Idursulfase, AL glucosidase alfa and Alpha1-Proteinase inhibitor enzyme replacement therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Enzyme Replacement Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on enzyme replacement therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for enzyme replacement therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The enzyme replacement therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Enzyme Type: Agalsidase Alfa; Agalsidase Beta; Galsulfase; Other Enzyme Types
  • 2) By Route Of Administration: Oral; Parenteral
  • 3) By Application: Gaucher Disease; Pompe Disease; Fabry Disease; Other Applications
  • 4) By End-Users: Hospitals; Infusion Centers; Other End-Users
  • Subsegments:
  • 1) By Agalsidase Alfa: Fabry Disease Treatment
  • 2) By Agalsidase Beta: Fabry Disease Treatment
  • 3) By Galsulfase: Mucopolysaccharidosis VI (MPS VI) Treatment
  • 4) By Other Enzyme Types: Alglucosidase Alfa; Idursulfase; Velaglucerase Alfa
  • Companies Mentioned: Biomarin Pharmaceutical Inc.; Leadiant Biosciences Inc.; Pfizer Inc.; Sanofi S.A.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Enzyme Replacement Therapy Market Characteristics

3. Enzyme Replacement Therapy Market Trends And Strategies

4. Enzyme Replacement Therapy Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Enzyme Replacement Therapy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Enzyme Replacement Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Enzyme Replacement Therapy Market Growth Rate Analysis
  • 5.4. Global Enzyme Replacement Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Enzyme Replacement Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Enzyme Replacement Therapy Total Addressable Market (TAM)

6. Enzyme Replacement Therapy Market Segmentation

  • 6.1. Global Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Agalsidase Alfa
  • Agalsidase Beta
  • Galsulfase
  • Other Enzyme Types
  • 6.2. Global Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Parenteral
  • 6.3. Global Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gaucher Disease
  • Pompe Disease
  • Fabry Disease
  • Other Applications
  • 6.4. Global Enzyme Replacement Therapy Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Infusion Centers
  • Other End-Users
  • 6.5. Global Enzyme Replacement Therapy Market, Sub-Segmentation Of Agalsidase Alfa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fabry Disease Treatment
  • 6.6. Global Enzyme Replacement Therapy Market, Sub-Segmentation Of Agalsidase Beta, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fabry Disease Treatment
  • 6.7. Global Enzyme Replacement Therapy Market, Sub-Segmentation Of Galsulfase, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Mucopolysaccharidosis VI (MPS VI) Treatment
  • 6.8. Global Enzyme Replacement Therapy Market, Sub-Segmentation Of Other Enzyme Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alglucosidase Alfa
  • Idursulfase
  • Velaglucerase Alfa

7. Enzyme Replacement Therapy Market Regional And Country Analysis

  • 7.1. Global Enzyme Replacement Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Enzyme Replacement Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Enzyme Replacement Therapy Market

  • 8.1. Asia-Pacific Enzyme Replacement Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Enzyme Replacement Therapy Market

  • 9.1. China Enzyme Replacement Therapy Market Overview
  • 9.2. China Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Enzyme Replacement Therapy Market

  • 10.1. India Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Enzyme Replacement Therapy Market

  • 11.1. Japan Enzyme Replacement Therapy Market Overview
  • 11.2. Japan Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Enzyme Replacement Therapy Market

  • 12.1. Australia Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Enzyme Replacement Therapy Market

  • 13.1. Indonesia Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Enzyme Replacement Therapy Market

  • 14.1. South Korea Enzyme Replacement Therapy Market Overview
  • 14.2. South Korea Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Enzyme Replacement Therapy Market

  • 15.1. Western Europe Enzyme Replacement Therapy Market Overview
  • 15.2. Western Europe Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Enzyme Replacement Therapy Market

  • 16.1. UK Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Enzyme Replacement Therapy Market

  • 17.1. Germany Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Enzyme Replacement Therapy Market

  • 18.1. France Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Enzyme Replacement Therapy Market

  • 19.1. Italy Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Enzyme Replacement Therapy Market

  • 20.1. Spain Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Enzyme Replacement Therapy Market

  • 21.1. Eastern Europe Enzyme Replacement Therapy Market Overview
  • 21.2. Eastern Europe Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Enzyme Replacement Therapy Market

  • 22.1. Russia Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Enzyme Replacement Therapy Market

  • 23.1. North America Enzyme Replacement Therapy Market Overview
  • 23.2. North America Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Enzyme Replacement Therapy Market

  • 24.1. USA Enzyme Replacement Therapy Market Overview
  • 24.2. USA Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Enzyme Replacement Therapy Market

  • 25.1. Canada Enzyme Replacement Therapy Market Overview
  • 25.2. Canada Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Enzyme Replacement Therapy Market

  • 26.1. South America Enzyme Replacement Therapy Market Overview
  • 26.2. South America Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Enzyme Replacement Therapy Market

  • 27.1. Brazil Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Enzyme Replacement Therapy Market

  • 28.1. Middle East Enzyme Replacement Therapy Market Overview
  • 28.2. Middle East Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Enzyme Replacement Therapy Market

  • 29.1. Africa Enzyme Replacement Therapy Market Overview
  • 29.2. Africa Enzyme Replacement Therapy Market, Segmentation By Enzyme Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Enzyme Replacement Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Enzyme Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Enzyme Replacement Therapy Market Competitive Landscape And Company Profiles

  • 30.1. Enzyme Replacement Therapy Market Competitive Landscape
  • 30.2. Enzyme Replacement Therapy Market Company Profiles
    • 30.2.1. Biomarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Leadiant Biosciences Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Enzyme Replacement Therapy Market Other Major And Innovative Companies

  • 31.1. Johnson & Johnson Services Inc.
  • 31.2. Alexion Pharmaceuticals Inc.
  • 31.3. Recordati Rare Diseases Inc.
  • 31.4. Sangamo Therapeutics Inc.
  • 31.5. JCR Pharmaceuticals Co. Ltd.
  • 31.6. Horizon Pharma Public Limited Company
  • 31.7. Protalix Biotherapeutics Ltd.
  • 31.8. Amicus Therapeutics Inc.
  • 31.9. AstraZeneca plc
  • 31.10. Novartis AG
  • 31.11. Roche Holding AG
  • 31.12. GlaxoSmithKline plc
  • 31.13. Merck & Co. Inc.
  • 31.14. Eli Lilly and Company
  • 31.15. Bristol-Myers Squibb Company

32. Global Enzyme Replacement Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Enzyme Replacement Therapy Market

34. Recent Developments In The Enzyme Replacement Therapy Market

35. Enzyme Replacement Therapy Market High Potential Countries, Segments and Strategies

  • 35.1 Enzyme Replacement Therapy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Enzyme Replacement Therapy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Enzyme Replacement Therapy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer